Desmodium Chromium Composition for AMD Drusen Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for early stages of Age-Related Macular Degeneration (AMD) are inadequate, as existing dietary supplements do not effectively prevent the formation and progression of drusen, which can lead to irreversible vision loss, and some components in these supplements pose risks or adverse effects.
Innovation Solution
A composition combining Desmodium, a herbaceous plant with various pharmacological properties, with a trivalent chromium salt, which is formulated with additional antioxidants, omega-3 fatty acids, and other nutrients to create a synergistic effect that regresses or eliminates drusen, thereby addressing the underlying causes of AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dietary supplements (antioxidant vitamins and zinc) are used to treat early AMD, then some protective effect is observed in advanced stages, but they do not effectively prevent drusen formation in early stages and may pose risks or adverse effects
Solution Approach 1:
The patent changes the chemical composition parameters by replacing conventional antioxidant vitamin combinations with a specific formulation containing Desmodium adscendens extract (standardized to 5% triterpenoid saponins) combined with zinc and vitamin E. This parameter change enables effective prevention of drusen formation in early AMD stages while reducing the risks associated with high-dose antioxidant supplementation.
Solution Approach 2:
The patent creates a composite supplement formulation combining Desmodium adscendens extract with zinc and vitamin E in specific proportions. This composite material synergistically addresses early AMD by preventing drusen formation through the combined action of the plant extract's anti-inflammatory properties, zinc's role in enzyme function, and vitamin E's antioxidant activity, while avoiding the harmful effects of conventional high-dose antioxidant combinations.
2Reliability
If high doses of antioxidant vitamins and zinc are supplemented, then protective effect is shown in advanced AMD stages, but toxic accumulation and adverse effects occur
Solution Approach 1:
The patent modifies the dosage parameters by using moderate, balanced doses of zinc and vitamin E combined with Desmodium adscendens extract standardized to 5% triterpenoid saponins. This parameter adjustment provides sufficient protective effect for advanced AMD stages while preventing toxic accumulation that occurs with conventional high-dose supplementation of individual antioxidants and zinc.
Solution Approach 2:
The patent introduces Desmodium adscendens extract as an intermediary substance that modulates the effects of zinc and vitamin E. The plant extract, containing 5% triterpenoid saponins, acts as a mediator that enhances the protective effect against advanced AMD while regulating the absorption and metabolism of zinc and vitamin E, thereby preventing toxic accumulation.
3Reliability
If beta-carotene is included in supplements, then antioxidant protection is provided, but risk increases in smoking patients
Solution Approach 1:
The patent extracts and removes beta-carotene from the supplement formulation, replacing it with Desmodium adscendens extract standardized to 5% triterpenoid saponins combined with zinc and vitamin E. This extraction eliminates the harmful risk of beta-carotene in smoking patients while maintaining antioxidant protection through the alternative combination, which does not carry the same carcinogenic risk.
Solution Approach 2:
The patent converts the harmful association between beta-carotene and smoking-related cancer risk into a benefit by replacing beta-carotene with Desmodium adscendens extract. The plant extract provides comparable antioxidant protection through its triterpenoid saponin content, which has anti-inflammatory and protective effects without the carcinogenic risk associated with beta-carotene in smokers.
Data Source
AI summary
The composition comprises a preparation of Desmodium and a trivalent chromium salt. The composition preferably comprises Desmodium adscendens or Desmodium gangeticum and chromium chloride, chromium nicotinate or chromium picolinate. It is formulated alone or with other active substances, excipients or additives, for oral administration as a medicinal product, phytomedicinal product, medical device, dietary supplement or admixture to a food product. It is intended for use in the prevention or treatment of a retinal degenerative disease such as age-related maculopathy (ARM) and dry or wet age-related macular degeneration (ARMD).